In HER2-positive breast cancer, trastuzumab-modified nanocarriers lowered the incidence of cardiac complications to 2.4% while enhancing therapeutic outcomes (Ngamcherdtrakul et al., 2015; Meng et al., 2018). Here, ERBB2 is linked to breast carcinoma.